Table 2.
Comparison of the demographic and medical characteristics between both groups
| Variables | Magnet Group | Sham Group | P valueb |
|---|---|---|---|
| Mean ± SDa | Mean ± SD | ||
| Age (y) | 58.31 ± 9.25 | 61.34 ± 5.87 | 0.28 |
| Weight (kg) | 78.75 ± 13.45 | 75.40 ± 15.12 | 0.35 |
| Height (cm) | 163.53 ± 9.76 | 163.90 ± 8.44 | 0.93 |
| BMIc (kg/ m2) | 29.52 ± 4.80 | 27.98 ± 4.58 | 0.19 |
| Sex, No. (%) | |||
| Males | 10 (31.3) | 10 (31.3) | 1.00 |
| Females | 22 (68.7) | 22 (68.7) | |
| Duration of incidence of diabetes (m) | 165.03 ± 104.16 | 175.88 ± 87.73 | 0.53 |
| Duration of the beginning of diabetic neuropathy (m) | 63.88 ± 47.65 | 57.31 ± 43.02 | 0.68 |
| Duration of exercise a week (h) | 3.37 ± 3.43 | 2.92 ± 2.91 | 0.67 |
| Pre-FBGd (mg/dL) | 170.88 ± 57.52 | 162.25 ± 56.08 | 0.54 |
| Hb A1C (%) | 8.04 ± 1.17 | 7.90 ± 1.10 | 0.61 |
| Drugs for diabetes, No (%) | |||
| Oral | 16 (50) | 17 (53.1) | 0.96 |
| Insulin | 1 (3.1) | 1 (3.1) | |
| Both | 15 (46.9) | 14 (43.8) | |
| Concomitant medications for neuropathy, No (%) | |||
| None | 14 (43.8) | 16 (50) | 0.84 |
| Gabapentin 300 daily | 3 (9.4) | 3 (9.4) | |
| Vit B1 300 daily | 3 (9.4) | 2 (6.2) | |
| Vit D3 50000 monthly | 6 (18.8) | 6 (18.8) | |
| Vit B1 and Vit D3 | 3 (9.4) | 4 (12.5) | |
| Gabapentin and Vit B1 | 2 (6.2) | 0 (0) | |
| Gabapentin and Vit D3 | 0 (0) | 1 (3.1) | |
| Gabapentin and Vit B1 and Vit D3 | 1 (3.1) | 0 (0) | |
| Medical history, No (%) | |||
| Blood pressure | 15 (46.9) | 17 (53.1) | 0.62 |
| Kidney diseases | 5 (15.6) | 3 (9.4) | 0.70 |
| Cardiac diseases | 10 (31.2) | 11 (34.4) | 0.79 |
| Mental disorders | 2 (6.2) | 1 (3.1) | 1.00 |
| Ocular diseases | 17 (53.1) | 14 (43.8) | 0.45 |
aSD standard deviation, bP-value probability value, cBMI body mass index, dFBG fasting blood glucose